20:30 , Dec 17, 2018 |  BioCentury  |  Finance

Versant’s base case

Versant Ventures plans to allocate more funding per start-up out of its newest funds, reflecting the firm’s shift towards building stand-alone companies with large portfolios. On Monday, Versant closed Versant Venture Capital VII at $600...
23:28 , Nov 2, 2018 |  BioCentury  |  Finance

Bye-bye, build-to-buy

As another Inception Sciences Inc. company secures an exit, Versant Ventures plans to move away from its build-to-buy model to focus on creating stand-alone companies with broader portfolios and investor syndicates. On Oct. 31, Ophthotech...
00:38 , Apr 28, 2017 |  BC Innovations  |  Finance

Hatching VC incubators

While more VCs have created venture incubators to nurture early concepts into full-fledged start-ups, they are aligned more on the need to incubate than on how best to do it. Indeed, a collection of VCs...
01:12 , Jan 7, 2017 |  BC Extra  |  Financial News

Financial tracks

Versant Ventures named Clare Ozawa managing director and named Alex Mayweg and Mary Haak-Frendscho venture partners. Ozawa was COO at the firm's Inception Sciences Inc. (San Diego, Calif.) company creation operation, and will remain in...
07:00 , Apr 18, 2016 |  BioCentury  |  Finance

Highline's hunter

Now that Versant Ventures' Highline Therapeutics has hired a veteran drug hunter and secured lab space in New York City, the incubator expects to be able to launch companies with fleshed out pipelines. Last week,...
00:22 , Apr 13, 2016 |  BC Extra  |  Financial News

Financial tracks

Versant Ventures promoted Jerel Davis to managing director from partner, and Carlo Rizzuto to partner from venture partner. The firm also hired Luca Santarelli as a venture partner. He was SVP and global head of...
08:00 , Jan 25, 2016 |  BioCentury  |  Strategy

Formative years

VCs that spend a large chunk of their time and capital creating companies from scratch are planning to continue regardless of what happens with the financial markets. Although de novo company formation takes a lot...
08:00 , Nov 2, 2015 |  BioCentury  |  Finance

No stone left unturned

Versant Ventures added to its Canada playbook last week by backing a biotech that has been working in stealth mode to develop an oncolytic virus that is expected to be more potent than first-generation products....
07:00 , Aug 24, 2015 |  BioCentury  |  Finance

Versant bites at the apple

Versant Ventures was to announce on Monday this week that it has selected New York City as the newest leg of its geographic strategy. The firm expects the region will fit the mold of its...
07:00 , May 4, 2015 |  BioCentury  |  Finance

Build to bye-bye

Versant Ventures last week saw its first build-to-buy company get taken out by Celgene Corp. (NASDAQ:CELG) and another enter into a partnership with Celgene, but the VC doesn't expect its recently closed fifth fund to...